Trial Profile
A multi-center, open-lable, phase I trial of RG-101 in healthy volunteers and patients with hepatitis C virus infection with severe renal impairment
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 31 Jan 2017
Price :
$35
*
At a glance
- Drugs RG 101 (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- 25 Jan 2017 According to a Regulus Therapeutics media release, the FDA has requested the final safety and efficacy data from on-going RG-101 trials for reconsidering of the clinical hold on RG-101 program. Data will be available after completion of 48 weeks of follow up, anticipated in the fourth quarter 2017.
- 27 Jun 2016 According to a Regulus Therapeutics media release, the company is on track to deliver follow-up results from this study at upcoming relevant scientific meetings.
- 27 Jun 2016 Status changed from recruiting to active, no longer recruiting, according to a Regulus Therapeutics media release.